|
| Saturday, November 20, 2010 |
|
| NASH and ASH: The Latest |
Amy McClune, MD |
 |
|
| Encephalopathy Update |
Stuart Gordon, MD, FACP, FACG |
|
|
| Rifaximin: HE and Beyond |
Mark Pimentel, MD, FRCPC |
|
|
| Cases and Discussions |
Moderator:
Steven Huy-Han, MD, AGAF
Panelists:
Amy McClune, MD
Stuart Gordon, MD, FACP, FACG
Mark Pimentel, MD, FRCPC |
|
|
| Hepatitis C: Telaprevir and Boceprevir |
Fred Poordad, MD |
|
|
| Hepatitis C: Other Direct Acting Antivirals |
Eric Lawitz, MD |
|
|
| Hepatitis C Clinical Cases |
Moderator:
Fred Poordad, MD
Panelists:
Stuart Gordon, MD, FACP, FACG
Eric Lawitz, MD
Paul Pockros, MD |
|
|
| Sunday, November 21, 2010 |
|
| Portal Hypertension Update |
Bruce Runyon, MD |
|
|
| Hepatorenal Syndrome: Diagnosis and Treatment |
Francisco Durazo, MD |
|
|
| Liver Cancer: What is the best therapy if transplant is out |
Henrik Petrowsky, MD |
|
|
| Cases and Panel Discussion |
Moderator:
John Donovan, MD
Panelists:
Bruce Runyon, MD
Francisco Durazo, MD
Henrik Petrowsky, MD |
|
|
| HBV Oral Therapies and Interferons |
Michael Fried, MD |
|
|
| HBV Resistance and Safety 2010 |
Sammy Saab, MD, MPH, AGAF |
|
|
| HBV Research: Where Are We Going? |
Tram Tran, MD |
|
